Finding the best sequence for Next-Gen breast cancer drugs
NCT ID NCT07162259
Summary
This study aims to find the best order to use two newer, targeted breast cancer drugs (called ADCs) after standard first-line treatment stops working. It will enroll 40 adults with advanced HR+/HER2- breast cancer whose cancer has progressed on prior therapy. Researchers will compare which drug sequence works better to control the cancer and improve survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xi'an International Medical Center Hospital
Xi'an, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.